Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Danqi Fu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5028325387. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. The c-Myc-USP14-PFKP axis sustains chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2026.101385↗
  2. Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling. Co-author DOI 10.1136/gutjnl-2024-333638↗
  3. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  4. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  5. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  6. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  7. Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41421-021-00366-y↗
  8. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 7 shared papers, 2019–2025 · strength 0.99
  2. Shengyu Yang · 6 shared papers, 2019–2025 · strength 0.85
  3. Tiansuo Zhao · 5 shared papers, 2019–2025 · strength 0.71
  4. Chongbiao Huang · 5 shared papers, 2019–2024 · strength 0.65
  5. Song Gao · 5 shared papers, 2019–2024 · strength 0.65
  6. Jing Liu · 5 shared papers, 2019–2024 · strength 0.65
  7. Xiuchao Wang · 4 shared papers, 2019–2024 · strength 0.51
  8. Chuntao Gao · 2 shared papers, 2023–2025 · strength 0.34
  9. Wenna Jiang · 3 shared papers, 2019–2023 · strength 0.34
  10. Tianxing Zhou · 3 shared papers, 2019–2023 · strength 0.34
  11. Yongjie Xie · 2 shared papers, 2023 · strength 0.26
  12. Chunhua She · 1 shared paper, 2026 · strength 0.24
  13. Jing Hu · 1 shared paper, 2026 · strength 0.24
  14. Pengyu Wang · 1 shared paper, 2026 · strength 0.24
  15. Xugang Sun · 1 shared paper, 2025 · strength 0.20
  16. Wenrun Cai · 1 shared paper, 2025 · strength 0.20
  17. Haorui Li · 1 shared paper, 2025 · strength 0.20
  18. Chao Xu · 1 shared paper, 2024 · strength 0.17
  19. Hui Li · 1 shared paper, 2024 · strength 0.17
  20. Peng Xie · 1 shared paper, 2024 · strength 0.17
  21. Yukuan Feng · 1 shared paper, 2024 · strength 0.17
  22. Huizhi Sun · 1 shared paper, 2024 · strength 0.17
  23. Yang Liu · 1 shared paper, 2022 · strength 0.15
  24. Xiaoying Fan · 1 shared paper, 2022 · strength 0.15
  25. Ping Lü · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.